Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    Minerva Neurosciences, Inc. (NERV)

    2.3200 +0.0800 (+3.57%)
    At close: October 30 at 4:00:01 PM EDT
    2.3200 0.0000 (0.00%)
    After hours: October 30 at 5:23:01 PM EDT
    Trade NERV on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for NERV
    • Previous Close 2.2400
    • Open 2.2700
    • Bid 1.6500 x 200
    • Ask 2.5400 x 200
    • Day's Range 1.9600 - 2.3200
    • 52 Week Range 1.9600 - 8.8000
    • Volume 394,310
    • Avg. Volume 187,582
    • Market Cap (intraday) 110.774M
    • Beta (5Y Monthly) -0.12
    • PE Ratio (TTM) --
    • EPS (TTM) -36.1200
    • Earnings Date (est.) --
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 10.33
    • Zacks Rating Neutral

    Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

    www.minervaneurosciences.com

    7

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Minerva Neurosciences, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    NERV
    42.29%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    NERV
    42.57%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    NERV
    42.43%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    NERV
    79.29%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings 16.65M
    Profit Margin 0.00%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -200M
    -100M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    7.00
    10.33 Average
    2.3200 Current
    14.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 8/14/2026
    Analyst Jefferies
    Rating Action Upgrade
    Rating Buy
    Price Action Raises
    Price Target 7.5 -> 10
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -28.42%

    • Return on Equity (ttm)

      --

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -394.35M

    • Diluted EPS (ttm)

      -36.1200

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      75.27M

    • Total Debt/Equity (mrq)

      --

    • Levered Free Cash Flow (ttm)

      -8.86M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    KALA
    CTMX
    CRVS
    ATXI
    ALDX
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: